Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Mucosal Lentiginous Melanoma × nilotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26 Leukemia, Myeloid, Chronic-Phase 11 Leukemia 6 Gastrointestinal Stromal Tumors 6 Neoplasm Metastasis 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Melanoma 3 Synovitis, Pigmented Villonodular 2 Recurrence 2 Ovarian Neoplasms 2 Neoplasms 2 Hematologic Diseases 2 Substance Withdrawal Syndrome 1 Peritoneal Neoplasms 1 Neoplastic Processes 1 Neoplasm, Residual 1 Necrosis 1 Myeloproliferative Disorders 1 Mucosal Lentiginous Melanoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid 1 Glioma 1 Giant Cell Tumor of Tendon Sheath 1 Genital Neoplasms, Female 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Disease Progression 1 Colorectal Neoplasms 1 Bronchiolitis Obliterans Syndrome 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01395121 2017-06-08

NICAM

Institute of Cancer Research, United Kingdom

Phase 2 Completed

Mucosal Lentiginous Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡